Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction-Reference-Cited by-同舟云学术

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Published:2024-09 Issue: Volume: Page:
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Solomon Scott D.¹^ORCID,McMurray John J.V.¹^ORCID,Vaduganathan Muthiah¹^ORCID,Claggett Brian¹,Jhund Pardeep S.¹,Desai Akshay S.¹,Henderson Alasdair D.¹,Lam Carolyn S.P.¹,Pitt Bertram¹,Senni Michele¹,Shah Sanjiv J.¹,Voors Adriaan A.¹,Zannad Faiez¹^ORCID,Abidin Imran Zainal¹,Alcocer-Gamba Marco Antonio¹,Atherton John J.¹,Bauersachs Johann¹,Chang-Sheng Ma¹,Chiang Chern-En¹,Chioncel Ovidiu¹,Chopra Vijay¹,Comin-Colet Josep¹,Filippatos Gerasimos¹,Fonseca Cândida¹,Gajos Grzegorz¹,Goland Sorel¹,Goncalvesova Eva¹,Kang Seokmin¹,Katova Tzvetana¹,Kosiborod Mikhail N.¹,Latkovskis Gustavs¹,Lee Alex Pui-Wai¹,Linssen Gerard C.M.¹,Llamas-Esperón Guillermo¹,Mareev Vyacheslav¹,Martinez Felipe A.¹,Melenovský Vojtěch¹,Merkely Béla¹^ORCID,Nodari Savina¹,Petrie Mark C.¹,Saldarriaga Clara Inés¹,Saraiva Jose Francisco Kerr¹^ORCID,Sato Naoki¹,Schou Morten¹,Sharma Kavita¹,Troughton Richard¹,Udell Jacob A.¹,Ukkonen Heikki¹,Vardeny Orly¹,Verma Subodh¹,von Lewinski Dirk¹^ORCID,Voronkov Leonid¹,Yilmaz Mehmet Birhan¹,Zieroth Shelley¹,Lay-Flurrie James¹,van Gameren Ilse¹,Amarante Flaviana¹,Kolkhof Peter¹,Viswanathan Prabhakar¹

Affiliation:

1. From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann...

Funder

Bayer

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2407107

Reference21 articles.

1. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

2. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

3. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

4. Spironolactone for Heart Failure with Preserved Ejection Fraction

5. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Editor-in-Chief: Our Hirsch index, current issue, news from ESC 2024, trials and new guidelines, protection and long COVID;Heart, Vessels and Transplantation;2024-09-10

2. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis;The Lancet;2024-09

3. European Society of Cardiology Congress 2024 Meeting: Heart Failure Highlights;Journal of Cardiac Failure;2024-09

4. Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?;Journal of the American College of Cardiology;2024-09

5. Mineralocorticoid Antagonism in Heart Failure;JACC: Heart Failure;2024-09